ClinicalTrials.Veeva

Menu

Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements

M.D. Anderson Cancer Center logo

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Preoperative
Inflammatory Breast Cancer (IBC)
Lymphedema
Bioimpedance Measurement

Treatments

Drug: Neoadjuvant therapy

Study type

Observational

Funder types

Other

Identifiers

NCT07855627
2026-0423
NCI-2026-07135 (Other Identifier)

Details and patient eligibility

About

To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.

Full description

Primary Objectives The primary objective is to reliably describe risk factors for development of BCRL in IBC using BIA.

Enrollment

150 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility Criteria All women≥18 years old with newly diagnosed inflammatory breast cancer without prior breast/axillary surgery who are eligible for standard of care (NST, MRM, and radiation therapy).

Exclusion Criteria Prior breast/axillary surgery. Participants with pacemakers or other implanted electronic medical devices. Participants with implanted metallic material. All vulnerable populations, including children, pregnant women, and cognitively impaired adult

Trial contacts and locations

1

Loading...

Central trial contact

Anthony Lucci, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems